USPTO 2015–2025 USPTO PatentsView US Corporation

Epizyme, Inc.

USPTO PatentsView assignee record - 150 granted patents across 16 technology areas, active 2015–2025. Filing-trend and competitive-moat analysis cross-referenced to USPTO Patent Public Search. Primary class: A61P (SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS).

Compiled byPlainPatent Editorial, US Patent Intelligence Editorial Team · May 15, 2026

Explore the portfolio See the ranking

150

Total patents granted

CPC technology areas

19.0

Avg claims per patent

-54%

5-year filing velocity

The verdict

Epizyme holds 150 US patents across 16 technology areas, rank #2,589 of 50,000 tracked assignees.

#2,589
of 50,000 US assignees by volume: Top 19%
by Innovation Score (47.3/100): 19.0
avg claims per patent: -54%
filing velocity, last 5 yrs

Portfolio overview

Epizyme, Inc. has been granted 150 US utility patents between 2015 and 2025, placing Epizyme, Inc. at rank #2,589 across all assignees tracked by PlainPatent. This portfolio spans 16 distinct Cooperative Patent Classification (CPC) subclasses, averaging 19.0 claims per patent with primary concentration in A61P (SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS). As a US Corporation, Epizyme, Inc. is one of the more focused assignees in the PatentsView dataset. By volume, Epizyme sits between Auckland Uniservices Limited (150 patents, rank #2,585) and Nextracker Llc (150 patents, rank #2,593) - the closest US assignees by grant volume. The composite Innovation Score of 47.3/100 blends portfolio volume, filing velocity, technology breadth, and claim depth into a single comparable measure drawn directly from USPTO PatentsView records.

Filing cadence tells the strategic story. Between 2020 and 2025 the company received 47 grants, compared with 103 in the 2015–2019 window, a -54% shift in five-year velocity. A cooling filing rate may reflect portfolio consolidation, shifting priorities, or reduced R&D throughput. The US Corporation classification further shapes interpretation, since corporate, government, and individual filers pursue patents for materially different reasons.

Claim depth and technology breadth together indicate competitive posture. Epizyme, Inc.'s 19.0 average claims per patent sits within the typical range for solid legal coverage without excessive prosecution cost, while concentration in 16 subclasses points to a focused technical program. Combined with portfolio volume, these signals let analysts, investors, and licensing professionals benchmark Epizyme, Inc. against peers pursuing similar technology classes.

Auckland Uniservi…

150
Canon Production…

150
Crowdstrike

150
Eberspächer Exhau…

150
Goodrich Lighting…

150
Harmonic Drive Sy…

150
Kyoraku

150
Nextracker

150
Epizyme ◀

150

What this shows Epizyme holds 150 patents at rank #2,589, shown against the 8 assignees closest to it in grant volume rather than the industry's largest filers.

Companies ranked near Epizyme

By rank, the assignees closest to #2,589 in granted patent volume.

Leaders in A61P (Specific Therapeutic Activity OF Chemical Compounds OR Me…)

Other assignees with the most granted patents in Epizyme's primary technology class.

Epizyme's Innovation Score vs. every tracked assignee

Composite of portfolio volume, filing velocity, technology breadth, and claim depth (0–100)

47 Top 19% higher than 81% of 50,000 US assignees

Each bar is a band; taller bars hold more US assignees. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count, share, and where it sits relative to this entry.

Source USPTO PatentsView, PlainPatent Innovation Score · 2015–2025

USPTO utility patent grants by year · 2015–2025

Grants by year

Teal-shaded recent years (2020–present) versus the 2015–2019 baseline. Full figures in the table below.

View data table

Epizyme, Inc. patent grants by year, 2015–2025
Year	Patents Granted	Share of Period
2015	19	12.7%
2016	19	12.7%
2017	26	17.3%
2018	22	14.7%
2019	17	11.3%
2020	11	7.3%
2021	10	6.7%
2022	4	2.7%
2023	12	8.0%
2024	9	6.0%
2025	1	0.7%

Which technologies does Epizyme, Inc. patent most?

A61P - SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS 133

C07D - HETEROCYCLIC COMPOUNDS 120

A61K - PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES 101

Y02A - TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE 21

C07H - SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS 13

C12N - MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA 12

G01N - INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES 10

C12Q - MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS ; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES 9

C07B - GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR 8

C12Y - ENZYMES 5

C07K - PEPTIDES 3

C07C - ACYCLIC OR CARBOCYCLIC COMPOUNDS 2

Y10T - TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION 2

A61N - ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY 1

G16B - BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY 1

Top 15 of 16 technology areas

Patent Moat Analysis

Portfolio Volume Moderate

Tech Breadth Focused

Claim Depth Standard

Velocity Declining

Where it ranks

Overall rank by patents

#2,589

Across all tracked assignees

Innovation Score

47.3 out of 100

View all rankings →

Data Source

USPTO PatentsView, US granted patents 2015–2025

How is Innovation Score calculated?

Frequently Asked Questions

How many patents does Epizyme, Inc. hold?

Epizyme, Inc. holds 150 US granted patents filed between 2015 and 2025, spanning 16 technology areas.

What is Epizyme, Inc.'s Innovation Score?

Epizyme, Inc. has an Innovation Score of 47.3 out of 100. This composite metric weighs portfolio volume (40%), filing velocity (20%), technology breadth (25%), and claim depth (15%).

What technology areas does Epizyme, Inc. focus on?

Epizyme, Inc.'s top technology area is A61P (SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS) with 133 patents. The company has filed patents in 16 CPC subclasses total.

Is Epizyme, Inc.'s patent filing rate increasing or decreasing?

Epizyme, Inc.'s recent filing velocity is -54% compared to the prior five-year period. Filing activity has slowed relative to earlier years.

What does claim depth mean for Epizyme, Inc.'s patents?

Epizyme, Inc.'s patents average 19.0 claims each. This falls within the standard range, providing solid legal coverage.

How is the Epizyme, Inc. patent data sourced?

All patent data comes from USPTO PatentsView, a public research dataset maintained by the United States Patent and Trademark Office covering US granted utility patents from 2015 to 2025.

How to use this portfolio

Epizyme's 150 grants land it in the top 19% by Innovation Score, but volume alone doesn't tell you where the strength sits.

Read that count against the largest US assignees before treating it as dominance - Epizyme ranks #2,589 of 50,000. Top 50 holders
Most of this portfolio concentrates in A61P - see who else leads that technology area. A61P leaders
Check what the four-part Innovation Score actually rewards before comparing it to another company. How the score works

Patent counts and the Innovation Score measure patenting activity, not commercial success or the legal strength of any patent. Many patents are filed defensively. Verify the status of an individual patent against official USPTO records.

Data sourced from USPTO PatentsView - official U.S. government patent data. See our methodology for computation details. Retrieved and formatted by PlainPatent Editorial

Disclaimer: This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from the USPTO PatentsView database. Consult a qualified professional before making decisions based on this data.

Read our methodology - how this data is sourced, computed, and verified.

Data sources used on this page

USPTO PatentsView - the disambiguated bulk patent-grant, assignee, and CPC data this page's figures are derived from. patentsview.org
Cooperative Patent Classification (CPC) - the joint USPTO/EPO classification scheme used to group patents by technology area. cooperativepatentclassification.org
USPTO Patent Public Search - the official interface to verify the status of any individual patent. ppubs.uspto.gov

Compiled byPlainPatent Editorial, US Patent Intelligence Editorial Team · May 15, 2026

Every figure on PlainPatent is rendered directly from USPTO source data, no number is typed in by an editor. This page draws directly on USPTO source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of May 2026.